Accéder au contenu
Merck

Hepatic differentiation of human pluripotent stem cells in miniaturized format suitable for high-throughput screen.

Stem cell research (2016-04-12)
Arnaud Carpentier, Ila Nimgaonkar, Virginia Chu, Yuchen Xia, Zongyi Hu, T Jake Liang
RÉSUMÉ

The establishment of protocols to differentiate human pluripotent stem cells (hPSCs) including embryonic (ESC) and induced pluripotent (iPSC) stem cells into functional hepatocyte-like cells (HLCs) creates new opportunities to study liver metabolism, genetic diseases and infection of hepatotropic viruses (hepatitis B and C viruses) in the context of specific genetic background. While supporting efficient differentiation to HLCs, the published protocols are limited in terms of differentiation into fully mature hepatocytes and in a smaller-well format. This limitation handicaps the application of these cells to high-throughput assays. Here we describe a protocol allowing efficient and consistent hepatic differentiation of hPSCs in 384-well plates into functional hepatocyte-like cells, which remain differentiated for more than 3weeks. This protocol affords the unique opportunity to miniaturize the hPSC-based differentiation technology and facilitates screening for molecules in modulating liver differentiation, metabolism, genetic network, and response to infection or other external stimuli.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Monoclonal Anti-α-Fetoprotein (AFP) antibody produced in mouse, ascites fluid, clone C3
Sigma-Aldrich
Anti-CYP2D6 antibody produced in rabbit, IgG fraction of antiserum